ELI LILLY AND COMPANY Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax of $19.10 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-04-30.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax · last filed 2015-04-30
- ELI LILLY AND COMPANY other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax for the quarter ending 2015-03-31 was $19.10M, a 198.44% increase year-over-year.
- ELI LILLY AND COMPANY other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax for the quarter ending 2014-09-30 was $6.50M, a 20.73% decline year-over-year.
- ELI LILLY AND COMPANY other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax for the quarter ending 2014-06-30 was $6.40M, a 93.94% increase year-over-year.
- ELI LILLY AND COMPANY other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax for the quarter ending 2014-03-31 was $6.40M, a 48.84% increase year-over-year.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax 9 month |
|---|---|---|---|
| 2015-03-31 | $19.10M 10-Q · filed 2015-04-30 | ||
| 2014-09-30 | $6.50M 10-Q · filed 2014-10-29 | $12.90M derived: sum of 2 quarters · filed 2014-10-29 | $19.30M 10-Q · filed 2014-10-29 |
| 2014-06-30 | $6.40M 10-Q · filed 2014-07-28 | $12.80M 10-Q · filed 2014-07-28 | |
| 2014-03-31 | $6.40M 10-Q · filed 2015-04-30 | ||
| 2013-09-30 | $8.20M 10-Q · filed 2014-10-29 | $11.50M derived: sum of 2 quarters · filed 2014-10-29 | $19.00M 10-Q · filed 2014-10-29 |
| 2013-06-30 | $3.30M 10-Q · filed 2014-07-28 | $7.60M 10-Q · filed 2014-07-28 | |
| 2013-03-31 | $4.30M 10-Q · filed 2014-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |